RxDoctor Payments Data

Maria Castillejos, MD

Ophthalmology · Chula Vista, CANPI 1043395098

Payments from drug & device makers

$2,272in general payments, 2019–2025

Across 112 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$749
  • Alcon$199
  • Genentech USA, Inc.$190
  • Harrow Eye, LLC$147
  • Regeneron Healthcare Solutions, Inc.$143
  • Novartis$107
  • plus $738 from 15 others

What the payments were for

  • Food & beverage$2,23598%
  • Education$372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,272 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$549,420
Medicare patients
431
Services billed
3,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost497$223,786
XiidraLifitegrast212$184,666
VyzultaLatanoprostene Bunod175$71,505
RestasisCyclosporine67$50,303
RhopressaNetarsudil Mesylate74$28,941
XdemvyLotilaner12$22,160
SimbrinzaBrinzolamide/Brimonidine Tart88$21,110
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol85$19,152
MieboPerfluorohexyloctane/Pf20$15,541
Brimonidine Tartrate210$15,136
RocklatanNetarsudil Mesylat/Latanoprost38$14,070
Brinzolamide63$13,183
Cyclosporine38$12,107
CombiganBrimonidine Tartrate/Timolol23$10,651
Alphagan PBrimonidine Tartrate32$10,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$749$295,265619 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$101$271,711407 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$66$43,011112 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$49$22,16012 claims
AlconSimbrinza$199$21,11088 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →